深度学习辅助MRI肿瘤影像组学动态预测HCC免疫治疗后病理完全缓解
本研究为多中心回顾性研究,从基线、治疗后及变化MRI中提取时间影像组学特征,构建并验证预测初始不可切除肝细胞癌(uHCC)转化治疗后病理完全缓解(pCR)的模型。Delta影像组学模型在测试集和验证集预测病灶水平pCR的AUC分别为0.835和0.783,均显著优于基线及术前模型;联合影像组学与AFP反应模型AUC达0.920(测试)和0.857(验证)。
要点
- Delta影像组学模型预测病灶水平pCR优于基线及术前模型。
- 联合影像组学与AFP反应模型预测pCR的AUC最高达0.920。
- 影像组学动态变化可无创评估pCR,辅助个体化治疗决策。
核心结论
- 动态影像组学变化可有效预测uHCC转化治疗后pCR,联合AFP反应可显著提升预测性能。
研究设计与样本
- 多中心回顾性研究,从基线、治疗后及变化MRI中提取时间影像组学特征。
- 训练队列n=78,内部测试队列n=32,独立验证队列n=44。
主要发现
- Delta影像组学模型预测病灶水平pCR的测试集AUC为0.835,验证集AUC为0.783。
- Delta模型显著优于基线模型(测试AUC 0.483,验证AUC 0.434,p<0.05)和术前模型(测试AUC 0.685,验证AUC 0.506,p<0.05)。
- 预测患者水平pCR时,影像组学模型测试集AUC为0.819,验证集AUC为0.781。
- 联合影像组学-AFP模型预测病灶水平pCR的测试集AUC为0.920,验证集AUC为0.857。
关键数值与推荐
- 血清AFP反应计算为log₁₀(术前AFP)/log₁₀(基线AFP)。
- 模型性能评估指标包括AUC、NPV、PPV、敏感度、特异度、校准和决策曲线分析。
临床怎么用
- 基于动态MRI影像组学与AFP反应的无创模型可用于术前评估uHCC转化治疗后pCR,潜在指导个体化治疗决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Pathological complete response (pCR) following conversion therapy for initially unresectable hepatocellular carcinoma (uHCC) remains challenging to predict preoperatively. This study developed and validated a model integrating clinicopathological and radiomic features of the tumor to predict pCR. METHODS: In this multicenter retrospective study, temporal radiomics features were extracted from baseline, post-treatment, and delta (change) MRIs. Serum AFP response was calculated as log₁₀(preoperative AFP)/log₁₀(baseline AFP). Univariate analysis, collinearity assessment, LASSO, and random forest were employed to perform feature selection. Fourteen machine learning models were benchmarked, with performance evaluated by using comprehensive metrics AUC, NPV, PPV, sensitivity, specificity, calibration, and decision curve analysis. RESULTS: The model was developed and validated in a training (n=78), an internal test (n=32), and an independent validation cohort (n=44). The delta radiomic model significantly outperformed both baseline (test AUC: 0.835 vs. 0.483, p <0.05; validation AUC: 0.783 vs. 0.434, p <0.05) and preoperative models (test AUC: 0.685, p <0.05; validation AUC: 0.506, p <0.05), demonstrating superior predictive performance and generalization capability in predicting lesion-level pCR. Notably, when predicting patient-level pCR, the radiomic model also showed robust discrimination, with AUCs of 0.819 in the test set and 0.781 in the validation set. The combined radiomics-AFP model achieved even higher AUCs of 0.920 (test) and 0.857 (validation) in predicting lesion-level pCR. CONCLUSIONS: Dynamic radiomic changes effectively predict pCR in uHCC after conversion therapy. Combining delta radiomics with AFP response significantly improves predictive performance, offering a non-invasive method for assessing pCR and potentially guiding personalized treatment decisions.
引用
- Zhou SQ, Wang LN, Wu LF, et al. Deep learning-assisted tumor radiomic dynamics on MRI predict pathological complete response in HCC undergoing immune-based therapy followed by hepatectomy. Hepatology. 2026. PMID: 41746634. doi:10.1097/HEP.0000000000001724
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。